News | Embolization devices | July 28, 2022

Instylla Announces Positive Results From Preclinical Studies of Embrace Hydrogel Embolic System in Hemorrhage Models 

a team of cardiovascular experts from the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, used experimental models to discover that a natural product found in plants including safflower holds promise for treating a pair of hereditary sudden cardiac death syndromes

Northeast Scientific Inc., pioneers in reprocessing single use peripheral vascular catheters, announced this week it has received FDA clearance for reprocessing the Philips Spectranetics 0.9mm OTW Turbo-Elite laser atherectomy catheter. 

Getty Images


July 28, 2022 —  Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. 

In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. Gandras et al. evaluatedi the ability of Embrace HES to achieve hemostasis in a porcine mesenteric artery hemorrhage model that replicates injury in humans. Results demonstrated that Embrace HES achieved complete, rapid, and durable embolization in 100% of the injured arteries with a mean delivery time of 5.3 minutes. There was no angiographic evidence of non-target embolization. 

"Embrace was effective in achieving hemostasis in an animal hemorrhage model without evidence of non-target embolization. This next generation liquid embolic has tremendous potential to play an important therapeutic role in a wide variety of clinical applications including hemorrhage and interventional oncology," commented Dr. Eric Gandras, Associate Chief, Vascular and Interventional Radiology at North Shore University Hospital, New York, and lead author of the study. 

In an independent study conducted by Dr. Kauvar et al., splenic injury and resulting hemorrhage were induced in swine models. A comparison was made between a control group having no embolic treatment to treatment groups that received embolization with Embrace HES, gel foam slurry, or coils. Under coagulopathic conditions, Embrace HES showed improved survival time and a significant reduction in bleeding compared to the control group, gel foam slurry, and coil treatments. 

About Embrace Hydrogel Embolic System: 

Embrace HES is an investigational device intended to be used to embolize peripheral arterial bleeds in vessels ≤ 6 mm. Embrace HES consists of two liquid precursors that solidify when simultaneously delivered into blood vessels, forming a soft hydrogel that fills the vessel lumens during the embolization procedure. The Embrace HES embolization uses no solvents, does not need sizing to the vessel diameter, and eliminates the possibility of catheter entrapment. Its main components are water and polyethylene glycol (PEG). 

For more information: https://www.instylla.com/ 

References: 

 i Eric John Gandras, Timothy Jarrett, Raymond Lareau, Evaluation of a Hydrogel Liquid Embolic Agent in a Porcine Mesenteric Hemorrhage Model, Journal of Vascular and Interventional Radiology, Volume 33, Issue 6, 2022,
Pages 653-659, ISSN 1051-0443, https://doi.org/10.1016/j.jvir.2022.02.022 

ii David S. Kauvar, I. Amy Polykratis, Rodolfo De Guzman, M. Dale Prince, Amber Voelker, Bijan S. Kheirabadi, Michael A. Dubick, Evaluation of a novel hydrogel intravascular embolization agent in a swine model of fatal uncontrolled solid organ hemorrhage and coagulopathy, JVS-Vascular Science, Volume 2, 2021, Pages 43-51,
ISSN 2666-3503, https://doi.org/10.1016/j.jvssci.2021.01.004 

Related Content

News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
Subscribe Now